Source: International Congress 2016 – Pulmonary hypertension: the clinic I



Rating:

Share or cite this content

Citations should be made in the following way:
Ioana R Preston (Boston, United States of America), Ioana Preston, Kelly Chin, Lilla Di Scala, Harrison Farber, Sean Gaine, Nazzareno Galiè, Hossein-Ardeschir Ghofrani, Marius M. Hoeper, Irene Lang, Vallerie McLaughlin, Ralph Preiss, Lewis J. Rubin, Gérald Simonneau, Olivier Sitbon, Victor F Tapson, Richard Channick. Management of selexipag interruptions in the GRIPHON study. Eur Respir J 2016; 48: Suppl. 60, 1870

Member's Comments

No comment yet.

Related content which might interest you: Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire: Results from the SYMPHONY study with macitentan Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Treatment with low-dose everolimus in patients with sporadic lymphangioleiomyomatosis (LAM) Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Intravenous prostacyclin for pulmonary hypertension: Patient’s perspective on complications Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Calculation of REVEAL scores for patients with PAH receiving riociguat in the PATENT-2 study Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Lymphangioma in patients with pulmonary lymphangioleiomyomatosis – Results of sirolimus treatment Source: International Congress 2016 – Orphan diseases I Year: 2016 Characteristics and outcomes of heritable pulmonary veno-occlusive disease due to EIF2AK4 mutations Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Epoprostenol dosing by concomitant therapies in the PROSPECT registry Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Transitioning sildenafil to taladafil in PAH patients is safe Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Pirfenidone post-authorization safety registry (PASSPORT) update Source: International Congress 2015 – Treatment of IPF Year: 2015 PAH-specific therapies improve survival in patients with pulmonary arterial hypertension associated with connective tissue diseases: A Russian single centre experience Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Integrated safety across six clinical trials of alpha-1 augmentation therapy Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Riociguat in pulmonary arterial hypertension: ERS/ESC risk assessment in PATENT Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Observational retrospective study on the treatment of pulmonary hypertension (PH) associated to pulmonary disease in patient with PH out of proportion Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 A retrospective study of depressive illness in patients with pulmonary hypertension (PH) at a specialist centre Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013